Cargando…

Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases

Despite advances in adjuvant therapy for breast cancer, bone remains the most common site of recurrence. The goal of therapy for these patients is palliative and focused on maximizing the duration and quality of their life, while concurrently minimizing any disease or treatment-related complications...

Descripción completa

Detalles Bibliográficos
Autores principales: Simos, Demetrios, Addison, Christina L., Kuchuk, Iryna, Hutton, Brian, Mazzarello, Sasha, Clemons, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470229/
https://www.ncbi.nlm.nih.gov/pubmed/26237063
http://dx.doi.org/10.3390/jcm2030067
_version_ 1782376734045241344
author Simos, Demetrios
Addison, Christina L.
Kuchuk, Iryna
Hutton, Brian
Mazzarello, Sasha
Clemons, Mark
author_facet Simos, Demetrios
Addison, Christina L.
Kuchuk, Iryna
Hutton, Brian
Mazzarello, Sasha
Clemons, Mark
author_sort Simos, Demetrios
collection PubMed
description Despite advances in adjuvant therapy for breast cancer, bone remains the most common site of recurrence. The goal of therapy for these patients is palliative and focused on maximizing the duration and quality of their life, while concurrently minimizing any disease or treatment-related complications. Bone metastases predispose patients to reduced survival, pain, impaired quality of life and the development of skeletal-related events. With an increased understanding of the pathophysiology of bone metastasis, effective treatments for their management have evolved and are now in widespread clinical use. This article will discuss the pathogenesis of bone metastases and review the key clinical evidence for the efficacy and safety of currently available systemic bone-targeted therapies in breast cancer patients with an emphasis on bisphosphonates and the receptor activator of nuclear factor kappa B ligand (RANKL) inhibitors. We will also discuss novel strategies and therapies currently in development.
format Online
Article
Text
id pubmed-4470229
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-44702292015-07-28 Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases Simos, Demetrios Addison, Christina L. Kuchuk, Iryna Hutton, Brian Mazzarello, Sasha Clemons, Mark J Clin Med Review Despite advances in adjuvant therapy for breast cancer, bone remains the most common site of recurrence. The goal of therapy for these patients is palliative and focused on maximizing the duration and quality of their life, while concurrently minimizing any disease or treatment-related complications. Bone metastases predispose patients to reduced survival, pain, impaired quality of life and the development of skeletal-related events. With an increased understanding of the pathophysiology of bone metastasis, effective treatments for their management have evolved and are now in widespread clinical use. This article will discuss the pathogenesis of bone metastases and review the key clinical evidence for the efficacy and safety of currently available systemic bone-targeted therapies in breast cancer patients with an emphasis on bisphosphonates and the receptor activator of nuclear factor kappa B ligand (RANKL) inhibitors. We will also discuss novel strategies and therapies currently in development. MDPI 2013-08-19 /pmc/articles/PMC4470229/ /pubmed/26237063 http://dx.doi.org/10.3390/jcm2030067 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Simos, Demetrios
Addison, Christina L.
Kuchuk, Iryna
Hutton, Brian
Mazzarello, Sasha
Clemons, Mark
Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases
title Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases
title_full Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases
title_fullStr Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases
title_full_unstemmed Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases
title_short Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases
title_sort bone-targeted agents for the management of breast cancer patients with bone metastases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470229/
https://www.ncbi.nlm.nih.gov/pubmed/26237063
http://dx.doi.org/10.3390/jcm2030067
work_keys_str_mv AT simosdemetrios bonetargetedagentsforthemanagementofbreastcancerpatientswithbonemetastases
AT addisonchristinal bonetargetedagentsforthemanagementofbreastcancerpatientswithbonemetastases
AT kuchukiryna bonetargetedagentsforthemanagementofbreastcancerpatientswithbonemetastases
AT huttonbrian bonetargetedagentsforthemanagementofbreastcancerpatientswithbonemetastases
AT mazzarellosasha bonetargetedagentsforthemanagementofbreastcancerpatientswithbonemetastases
AT clemonsmark bonetargetedagentsforthemanagementofbreastcancerpatientswithbonemetastases